How TRUMENBA® WorksTRUMENBA targets a gene found in >99% of invasive MenB disease strains1-3TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H binding protein (fHbp)—for which the gene is found in more than 99% of invasive MenB strains.1-3
The fHbp DiscoveryPfizer used a combined biochemical and immunological screening approach to identify surface-expressed proteins on MenB strains that were capable of inducing antibodies that could kill diverse meningococcal strains. During this process, fHbp elicited robust bactericidal responses.1
From 2011 through 2019Outbreaks of MenB strains have occurred at colleges across the country, such as Providence College, Rutgers University, UC Santa Barbara, and University of Oregon.5-8
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.ReferencesBased on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.1References:1. TRUMENBA® (Meningococcal Group B Vaccine). Prescribing information. Pfizer; 2024. 2. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379-389. 3. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744. 4. Harris SL, Donald RGK, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216-223. 5. Marshall GS, Dempsey AF, Srivistava A, Isturiz RE. US college students are at increased risk for serogroup B meningococcal disease. J Pediatric Infect Dis Soc. 2020;9(2):244-247. 6. Soeters HM, Dinitz-Sklar J, Kulkarni PA, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2017;23(5):867-869. 7. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 8. Data on file. Meningitis case outbreaks. Pfizer Inc., New York, NY. 9. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 10. Centers for Disease Control and Prevention. Meningococcal disease. Updated February 1, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/risk-factors/index.html 11. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 12. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. 13. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41. 14. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548-554. 15. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682.